GILD Stock — Gilead Sciences Inc.: Cash, EV, Pipeline

What they do

We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our Business Products We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas.

Source: 10-K FY2025 via SEC EDGAR

Share price

$166.89

Market cap

$207,000.1M

Cash

$6,437.0M

Enterprise value

$226,794.1M

Balance sheet

Cash	$6,437.0M
Debt	$26,231.0M
Net cash	-$19,794.0M
Enterprise value	$226,794.1M
Basic shares	1,240.3M shares
Fully diluted shares	1,321.2M shares
Fully diluted market cap	$220,495.1M
Cash per share	$5.19
Quarterly burn	+$3,573.0M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

1,272.0M

Pre-funded warrants

0.0M

Options

8.7M

RSUs

18.5M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

22.0M

FDSO

1,321.2M

Cap table as of 2026-06-30.

Price history

Loading GILD daily closes…

Loading price history…

Next catalyst

TAF · Now - Nov 24, 2026 Now · Phase 2 · Chronic Hepatitis B

Recently reported

emvistegrast Phase 2 Positive · 2026-10-19

GS-1427 · ulcerative colitis

Primary: Clinical remission at Week 12 in the Phase 2 study of emvistegrast (GS-1427) in moderate to severe ulcerative colitis (NCT06290934) — 200 mg daily emvistegrast for 12 weeks produced a 23% placebo-adjusted clinical remission rate, statistically significant (as reported by STAT)

· No patient numbers, absolute remission rates, or p-value disclosed in the accessible STAT report

· Gilead had issued no wire release on the data as of the poll

Safety: not disclosed

Figures auto-extracted, pending review.

Source release →

BIC/LEN Positive · 2026-08-27

Source release →

anitocabtagene autoleucel (anito-cel) Phase 2 Positive · 2026-07-01

iMMagine-1 · relapsed/refractory multiple myeloma

Source release →

Trodelvy Positive · 2026-06-24

Source release →

Sacituzumab Govitecan Phase 3 Negative · 2026-06-08

KEYNOTE-D46 · carcinoma, non-small-cell lung

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	TAF	Phase 2	Chronic Hepatitis B	—
Now - Nov 24, 2026 Now	Filgotinib	Phase 3	Ulcerative Colitis	—
GUIDEDEst. Nov 7, 2026 Now half midpoint	Livdelzi IDEAL in 2L primary biliary cholangitis	Not disclosed	2L primary biliary cholangitis	2H 2026
GUIDEDEst. Nov 7, 2026 Now half midpoint	Trodelvy ASCENT-03 in 1L mTNBC (PD-L1-)	Not disclosed	1L mTNBC (PD-L1-)	2H 2026
GUIDEDEst. Nov 7, 2026 Now half midpoint	Trodelvy ASCENT-04 in 1L mTNBC (PD-L1+)	Not disclosed	1L mTNBC (PD-L1+)	2H 2026
GUIDEDEst. Nov 7, 2026 Now half midpoint	Trodelvy ASCENT-GYN in 2L+ advanced endometrial cancer	Not disclosed	2L+ advanced endometrial cancer	2H 2026
Nov 12 - Dec 24 in 5d	Sacituzumab Govitecan-hziy	Phase 2	Solid Tumor	—
Nov 12 - Dec 24 in 5d	GS-4528	Phase 1	Solid Tumor	—
Nov 12 - Dec 24 in 5d	Sacituzumab govitecan	Phase 3	Triple Negative Breast Cancer; Metastatic Breast Cancer	—
GUIDEDDec 23, 2026 in 7 wks	anito-cel iMMagine-1 in 4L+ R/R multiple myeloma	Not disclosed	4L+ R/R multiple myeloma	by 23 December 2026
Dec 13, 2026 - Jan 24, 2027 in 5 wks	KITE-197	Phase 1	Relapsed/Refractory Large B-cell Lymphoma	—
Dec 13, 2026 - Jan 24, 2027 in 5 wks	GS-4571	Phase 1	Weight Management	—
Jan 12 - Feb 23 in 9 wks	Sacituzumab Govitecan-hziy	Phase 3	Metastatic Breast Cancer	—
Jan 12 - Feb 23 in 9 wks	Sacituzumab Govitecan-hziy	Phase 1	Advanced or Metastatic Solid Tumor; Liver Failure	—
Jan 12 - Feb 23 in 9 wks	GS-9911	Phase 1	Solid Tumors	—
Jan 12 - Feb 23 in 9 wks	Sacituzumab govitecan	Phase 1	Localized Muscle Invasive Bladder Urothelial Carcinoma; Muscle-Invasive Bladder Carcinoma	—
Feb 10 - Mar 24 in 14 wks	Remdesivir (RDV)	Phase 2	COVID - 19; Renal Transplant; SARS CoV 2 Infection	—
Feb 11 - Mar 25 in 14 wks	Sacituzumab Govitecan	Phase 2	Bladder Cancer; Bladder Urothelial Carcinoma; Bladder Neoplasm	—
Feb 12 - Mar 26 in 14 wks	Tilpisertib Fosmecarbil	Phase 2	Ulcerative Colitis	—
Feb 12 - Mar 26 in 14 wks	Domvanalimab	Phase 2	Gastrointestinal Tract Malignancies	—
Mar 14 - Apr 25 in 4 mo	Anti-OX40 Antibody PF-04518600	Phase 2	Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer	—
Mar 15 - Apr 26 in 4 mo	Sacituzumab Govitecan-hziy	Phase 3	Triple Negative Breast Cancer; PD-L1 Positive	—
Mar 15 - Apr 26 in 4 mo	Debio 0123 and Sacituzumab govitecan	Phase 2	Advanced Breast Cancer	—
Apr 12 - May 24 in 5 mo	Sacituzumab Govitecan-hziy (SG)	Phase 2	Non-small Cell Lung Cancer	—
Apr 12 - May 24 in 5 mo	Domvanalimab	Phase 2	Head and Neck Squamous Cell Carcinoma	—
Apr 12 - May 24 in 5 mo	Oral Lenacapavir	Phase 2	HIV-1-infection	—
Apr 12 - May 24 in 5 mo	GS-0151	Phase 1	Rheumatoid Arthritis	—
May 11 - Jun 22 in 6 mo	Capecitabine	Phase 3	HER2-negative Breast Cancer; Triple Negative Breast Cancer	—
Jun 12 - Jul 24 in 7 mo	Sacituzumab Govitecan-hziy	Phase 2	Advanced Solid Tumor; Metastatic Triple-Negative Breast Cancer; HR+/HER2- Metastatic Breast Cancer	—
Jun 12 - Jul 24 in 7 mo	Domvanalimab	Phase 2	Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer	—
Jun 12 - Jul 24 in 7 mo	Sacituzumab Govitecan	Phase 2	Breast Cancer	—
Jul 13 - Aug 24 in 8 mo	Sacituzumab govitecan-hziy (SG)	Phase 3	Triple Negative Breast Cancer	—
Aug 12 - Sep 23 in 9 mo	KTE-X19	Phase 2	Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia	—
Sep 12 - Oct 24 in 10 mo	GS-3242 Tablet	Phase 2	HIV-1-infection	—
Jan 3 - Feb 14 in 14 mo	COM503	Phase 1	Neoplasm; Cancer, Malignant Tumors	—
Jan 12 - Feb 23 in 14 mo	Domvanalimab	Phase 2	Advanced Non-Small Cell Lung Cancer	—
Jan 12 - Feb 23 in 14 mo	Sacituzumab govitecan	Phase 2	Differentiated Thyroid Cancer; Anaplastic Thyroid Cancer	—
Feb 12 - Mar 25 in 15 mo	Lepetegravir	Phase 3	HIV-1-Infection	—
Mar 12 - Apr 23 in 16 mo	GPC2 CAR T cells	Phase 1	Refractory Neuroblastoma; Relapsed Neuroblastoma; High-risk Neuroblastoma	—
May 13 - Jun 24 in 18 mo	Sacituzumab Govitecan-hziy	Phase 3	Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer	—
Jun 12 - Jul 24 in 19 mo	GS-5319	Phase 1	Advanced Solid Tumor	—
Jul 13 - Aug 24 in 20 mo	Zimberelimab	Phase 3	Non-small Cell Lung Cancer	—
Jul 13 - Aug 24 in 20 mo	Sacituzumab Govitecan-hziy (SG)	Phase 2	Triple Negative Breast Cancer	—
Jul 13 - Aug 24 in 20 mo	GS-2121	Phase 1	Advanced Solid Tumors	—
Jul 13 - Aug 24 in 20 mo	Sacituzumab govitecan	Phase 2	Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer	—
Aug 12 - Sep 23 in 21 mo	Sacituzumab Govitecan-hziy	Phase 3	Triple Negative Breast Cancer; PD-L1 Negative	—
Aug 12 - Sep 23 in 21 mo	Anitocabtagene Autoleucel	Phase 3	Multiple Myeloma	—
Oct 13 - Nov 24 in 24 mo	Lenacapavir Injection	Phase 3	HIV Pre-exposure Prophylaxis	—
Oct 13 - Nov 24 in 24 mo	GS-0201	Phase 1	Advanced Solid Tumors	—
Dec 13, 2028 - Jan 24, 2029 in 26 mo	Seladelpar 5 mg Capsule	Phase 3	Primary Biliary Cirrhosis	—
Jan 12 - Feb 23 in 27 mo	Denikitug	Phase 2	Advanced Microsatellite Stable Colorectal Cancer	—
Jan 12 - Feb 23 in 27 mo	Denikitug	Phase 1	Advanced Solid Tumor	—
Feb 12 - Mar 26 in 28 mo	GS-2426	Phase 1	Advanced Solid Tumors	—
Apr 12 - May 24 in 30 mo	Lenacapavir	Phase 3	HIV Infections	—
Apr 12 - May 24 in 30 mo	Lenacapavir	Phase 3	HIV-1-infection	—
Jul 13 - Aug 24 in 33 mo	Sacituzumab govitecan-hziy	Phase 3	Endometrial Cancer	—
Jul 13 - Aug 24 in 33 mo	KITE-363	Phase 1	Chronic Inflammatory Demyelinating Polyneuropathy; Myasthenia Gravis; Multiple Sclerosis	—
Aug 12 - Sep 23 in 34 mo	KITE-363	Phase 1	Systemic Lupus Erythematosus; Lupus Nephritis; Systemic Sclerosis	—
Sep 12 - Oct 24 in 35 mo	GS-0415	Phase 1	HIV -1 Infection	—
Oct 13 - Nov 24 in 36 mo	Zimberelimab (ZIM)	Phase 2	Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer	—
Oct 13 - Nov 24 in 36 mo	GS-1206	Phase 1	Solid Tumor	—
Oct 13 - Nov 24 in 36 mo	Sacituzumab govitecan	Phase 3	Triple Negative Breast Cancer	—
Nov 12 - Dec 24 in 37 mo	Sacituzumab Govitecan (SG)	Phase 3	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	—
Feb 12 - Mar 26 in 40 mo	GS-4321	Phase 2	Chronic Hepatitis Delta	—
Feb 12 - Mar 26 in 40 mo	Denikitug	Phase 2	HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma	—
Mar 15 - Apr 26 in 41 mo	Cyclophosphamide	Phase 2	Relapsed and/or Refractory B-cell Lymphoma	—
May 13 - Jun 24 in 43 mo	Sacituzumab Govitecan-hziy	Phase 2	Metastatic Urothelial Cancer	—
Aug 12 - Sep 23 in 46 mo	Lenacapavir	Phase 3	HIV-1-infection	—
Sep 12 - Oct 24 in 47 mo	Seladelpar	Phase 3	Primary Biliary Cholangitis	—
Nov 12 - Dec 24 in 49 mo	Axicabtagene Ciloleucel	Phase 3	Relapsed/Refractory Follicular Lymphoma	—
Nov 12 - Dec 24 in 49 mo	GS-3242 Tablet	Phase 3	HIV-1-infection	—
Apr 12 - May 24 in 54 mo	Axicabtagene Ciloleucel	Phase 3	High-risk Large B-cell Lymphoma (LBCL)	—
Jun 12 - Jul 24 in 56 mo	KITE-753	Phase 3	Relapsed or Refractory Large B-cell Lymphoma	—
May 12 - Jun 23 in 79 mo	Sacituzumab govitecan	Phase 3	Breast Cancer; Triple-negative Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Lenacapavir

Approved · Active Modality: capsid inhibitor (injection and tablet)

Aliases Yeztugo, Yeytuo

Target HIV-1 capsid

Indications

HIV pre-exposure prophylaxis (PrEP) (Approved)

Catalysts

— February 2, 2027

Status note First and only twice-yearly PrEP option in the U.S. (FDA approved; EC authorized as Yeytuo). Once-yearly injection formulation in Phase 3 for HIV PrEP.

Bictegravir + lenacapavir

Phase 3 · Active Modality: oral combination

Target HIV-1 (integrase + capsid)

Indications

HIV-1 treatment (virologically suppressed people) (Phase 3)

Catalysts

— August 27, 2026

Status note NDA accepted under priority review.

Islatravir + lenacapavir

Phase 3 · Active Modality: oral combination

Target HIV-1 (capsid + NRTTI)

Partnerships Merck: collaboration on oral islatravir + lenacapavir as long-acting HIV treatment

Indications

HIV-1 treatment (virologically suppressed people) (Phase 3)

Status note Merck's islatravir combined with Gilead's lenacapavir.

Anitocabtagene autoleucel

Phase 3 · Active Modality: CAR T-cell therapy (BCMA-directed)

Aliases anito-cel

Target BCMA

Partnerships Arcellx (acquired by Gilead; prior global co-development/co-commercialization collaboration)

Indications

Relapsed/refractory multiple myeloma (Phase 3)

Status note BLA filed for patients with 3+ prior regimens; Phase 3 ongoing in patients with 1-3 prior lines.

Sacituzumab govitecan-hziy

Approved · Active Modality: antibody-drug conjugate (topoisomerase inhibitor payload)

Aliases Trodelvy

Target Trop-2

Partnerships Merck: pembrolizumab combination programs (first-line PD-L1 positive mTNBC, adjuvant TNBC)

Indications

Metastatic triple-negative breast cancer (mTNBC) (Approved)
First-line PD-L1 negative mTNBC (Phase 3)
First-line PD-L1 positive mTNBC (with pembrolizumab) (Phase 3)
High-risk adjuvant TNBC (with pembrolizumab) (Phase 3)
Extensive-stage small cell lung cancer (Phase 3)
Second-line metastatic endometrial cancer (Phase 3)

Status note First-line metastatic NSCLC program (EVOKE-03, with Merck pembrolizumab) discontinued June 2026 per external Data Monitoring Committee recommendation; $1.75B NSCLC IPR&D impairment.

Axicabtagene ciloleucel

Phase 3 · Active Modality: CAR T-cell therapy

Aliases Yescarta

Target CD19

Indications

Second-line and later high-risk follicular lymphoma (FL) (Phase 3)
First-line high-risk large B-cell lymphoma (LBCL) (Phase 3)

Status note Approved CAR-T; in Phase 3 for earlier lines of therapy.

Domvanalimab + zimberelimab

Phase 3 · Active Modality: monoclonal antibodies (Fc-silent anti-TIGIT + anti-PD-1)

Target TIGIT + PD-1

Partnerships Arcus Biosciences: collaboration on domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1)

Indications

First-line metastatic NSCLC (with chemotherapy) (Phase 3)

Status note Evaluated in combination with chemotherapy.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04639986	Phase 3	Active, not recruiting	Sponsor	GILD	—	Metastatic Breast Cancer	—
NCT05382286	Phase 3	Active, not recruiting	Sponsor	GILD	MRK	Triple Negative Breast Cancer; PD-L1 Positive	—
NCT05633654	Phase 3	Recruiting	Sponsor	GILD	—	Triple Negative Breast Cancer	—
NCT06544733	Phase 3	Active, not recruiting	Sponsor	GILD	—	HIV-1-Infection	—
NCT05840211	Phase 3	Active, not recruiting	Sponsor	GILD	—	Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer	—
NCT05502237	Phase 3	Active, not recruiting	Sponsor	GILD	—	Non-small Cell Lung Cancer	—
NCT05382299	Phase 3	Active, not recruiting	Sponsor	GILD	—	Triple Negative Breast Cancer; PD-L1 Negative	—
NCT06413498	Phase 3	Active, not recruiting	Sponsor	GILD	—	Multiple Myeloma	—
NCT07047716	Phase 3	Active, not recruiting	Sponsor	GILD	—	HIV Pre-exposure Prophylaxis	—
NCT03301506	Phase 3	Active, not recruiting	Sponsor	GILD	—	Primary Biliary Cirrhosis	—
NCT07682961	Phase 3	Recruiting	Sponsor	GILD	—	HIV Infections	—
NCT07683000	Phase 3	Recruiting	Sponsor	GILD	—	HIV-1-infection	—

Sponsor-matched active trials from ClinicalTrials.gov (79 as sponsor, 111 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 190 active trials for Gilead Sciences on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	4,648	-1,703	0.03%	2026-08-14
OrbiMed Advisors	0	-59,600	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

GILD — Gilead Sciences Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

GILD — Gilead Sciences Inc.